Kahira Pharmaceuticals & Chemical Industries Co.
EEGX:CPCI590.26
EGP
+0.08
(+0.01%)
Kahira Pharmaceuticals & Chemical Industries Co.
EGX:CPCI
(Egyptian Exchange)
Recent
price
590.26
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Kahira Pharmaceuticals & Chemical Industries Co. is an Egypt-based pharmaceutical and chemical manufacturing company engaged in the research, development, formulation, production, marketing, and commercialization of human pharmaceuticals, veterinary medicines, dental preparations, nutritional supplements, medical cosmetics, and basic industrial and agricultural chemicals. Founded in 1962 and headquartered in Cairo, Egypt, the company operates as a publicly listed subsidiary of the state-owned Holding Company for Pharmaceuticals, Chemicals and Medical Supplies (HoldiPharma), which holds a controlling equity stake under the Egyptian Ministry of Public Business Sector. The company manufactures and distributes an extensive portfolio of therapeutic medications across key categories, including anti-infectives, cardiovascular treatments, central nervous system therapies, gastrointestinal agents, analgesics, anti-inflammatory drugs, respiratory medications, metabolic regulators, and dermatological remedies. Its product offerings span diverse dosage forms, including solid formulations such as immediate-release and sustained-release tablets, hard and soft gelatin capsules, effervescent granules, and bulk powders; liquid formulations such as oral syrups, suspensions, drops, and medicated mouthwashes; sterile injectable preparations such as ampoules, vials, dental anesthetic cartridges, and lyophilized powders; and topical and semi-solid preparations such as creams, ointments, gels, and suppositories. In addition to proprietary branded generics, the company provides toll manufacturing, contract development and packaging services, and licensed production under agreements with international pharmaceutical corporations. Geographically, the company serves the domestic Egyptian healthcare sector and exports across the Middle East and Africa, with key export markets including Sudan, Yemen, Iraq, Jordan, Libya, South Sudan, Somalia, Djibouti, Mali, Niger, and Senegal. In recent operational developments, Kahira Pharmaceuticals has executed extensive facility modernization and rehabilitation initiatives to upgrade its solid, liquid, and sterile production lines to meet updated Good Manufacturing Practice (GMP) standards accredited by the Egyptian Drug Authority (EDA) and international regulatory frameworks. Recent strategic and operational enhancements include the commissioning of upgraded mouthwash and raw material processing lines, the expansion of sterile dental cartridge manufacturing capacities, the integration of automated packaging and serialization tracking systems, and the ongoing execution of HoldiPharma-led strategic partnerships and toll-manufacturing contracts aimed at localizing pharmaceutical manufacturing and accelerating export expansion into new regional and international markets.